Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells

Arsenic trioxide (As2O3) is one of the arsenic compounds found in nature. As2O3 has recently been used to treat patients suffering from retinoic acid receptor (AML). It is of clinical interest to investigate whether As2O3 is also effective in treating solid tumors. Here, we report that As2O3 exhibited inhibitory effects on the proliferation of human breast cancer MCF‐7 cells in a dose‐ and time‐dependent manner. The 50% inhibitory concentration (IC50) of As2O3 in inhibiting proliferation of MCF‐7 cells were 8, 1.8, and 1.2 μM upon 1‐, 2‐, and 3‐day treatment, respectively. In elucidating the underlying action mechanisms, the results of experiments concerning DNA fragmentation and externalization indicated that As2O3 exerted its action on MCF‐7 cells via apoptosis, whereas the result of flow cytometry also indicated that As2O3 could induce mitochondrial mediated cell‐cycle arrest at G1 phase. Further studies by Western blot analysis indicated that As2O3 regulated apoptosis and the expression of cell‐cycle‐related proteins as it upregulated p53 protein level and downregulated bcl‐2 protein level. Results in present study indicated that As2O3 might also be a good candidate for treating breast cancer. © 2004 Wiley‐Liss, Inc.

[1]  John Calvin Reed,et al.  Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. , 1998, Cancer research.

[2]  K. Cowan,et al.  Ca2+/Mg(2+)-dependent endonuclease activation is an early event in VP-16-induced apoptosis of human breast cancer MCF7 cells in vitro. , 1995, Biochimica et biophysica acta.

[3]  K. Bhalla,et al.  Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.

[4]  D. Yee,et al.  Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. , 1999, Cancer letters.

[5]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[6]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[7]  J. Hickman,et al.  Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. , 1993, The EMBO journal.

[8]  E. Besa.  Acute promyelocytic leukemia. , 1991, Blood.

[9]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[10]  B. Katzenellenbogen,et al.  Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.

[11]  P. Ho,et al.  Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines , 2001, Cancer Chemotherapy and Pharmacology.

[12]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[13]  John Calvin Reed,et al.  Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. , 1994, Oncogene.

[14]  P. Pandolfi,et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. , 1998, The New England journal of medicine.

[15]  Yong-kui,et al.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. , 1999, Journal of the National Cancer Institute.

[16]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[17]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[18]  E. Sulpice,et al.  Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. , 1999, Experimental hematology.

[19]  M. Relling,et al.  Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia , 1997 .

[20]  T. Cotter,et al.  Regulation and measurement of oxidative stress in apoptosis. , 2002, Journal of immunological methods.

[21]  P. Walker,et al.  Separate pools of endonuclease activity are responsible for internucleosomal and high molecular mass DNA fragmentation during apoptosis. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  G. Lozano,et al.  PML, a growth suppressor disrupted in acute promyelocytic leukemia , 1994, Molecular and cellular biology.

[23]  R. Ohno,et al.  The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms , 1998, Leukemia.

[24]  G. Kroemer,et al.  Quantitation of mitochondrial alterations associated with apoptosis. , 2002, Journal of immunological methods.

[25]  K. Fung,et al.  Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. , 2002, Life sciences.

[26]  T. Hoang,et al.  Impaired Granulocytic Differentiation In Vitro in Hematopoietic Cells Lacking Retinoic Acid Receptors α1 and γ , 1998 .

[27]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[28]  D. Green,et al.  Caspase-3 Is the Primary Activator of Apoptotic DNA Fragmentation via DNA Fragmentation Factor-45/Inhibitor of Caspase-activated DNase Inactivation* , 1999, The Journal of Biological Chemistry.

[29]  E. Cao,et al.  Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. , 1999, European journal of cancer.

[30]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[31]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[32]  W. El-Deiry.  p21/p53, cellular growth control and genomic integrity. , 1998, Current topics in microbiology and immunology.

[33]  T. Hoang,et al.  Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma. , 1998, Blood.

[34]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.